Shares of Allogene Therapeutics, Inc. (ALLO) are tanking over 40% on Friday morning after the U.S. Food and Drug Administration put a clinical hold on the clinical-stage biotech company's cancer drug trial.
ALLO is currently trading at $14.10, down $10.28 or 42.16%, on the Nasdaq, on a volume of 11.9 million shares, above average volume of 700 thousand shares. The stock has traded between $13.70 and $44.92 in the 52-week period.
Allogene Therapeutics announced that that following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study, the FDA has placed a hold on the Company's AlloCAR T clinical trials.
The company said it will provide additional updates in the coming weeks following consultation with the FDA. The FDA continues to actively review the end of Phase 1 materials submitted in anticipation for an ALLO-501A pivotal Phase 2 trial.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.